Skip to main content

Table 2 Treatment-related adverse events (TRAEs)

From: Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

  All grade
n (%)
Grade 3–4
n (%)
All TRAEs (n) 20 (100.0) 11 (55.0)
 Platelet count decreased 16 (80.0) 9 (45.0)
 White blood cell count decreased 10 (50.0) 0 (0.0)
 Neutrophil count decreased 10 (50.0) 2 (10.0)
 Hypothyroidism 6 (30.0) 0 (0.0)
 Rash 5 (25.0) 0 (0.0)
 Alanine aminotransferase increased 5 (25.0) 0 (0.0)
 Aspartate aminotransferase increased 4 (20.0) 0 (0.0)
 Anemia 4 (20.0) 0 (0.0)
 Hepatic function abnormal 3 (15.0) 1 (5.0)
 Vomiting 3 (15.0) 0 (0.0)
 Nausea 2 (10.0) 0 (0.0)
 Hyperchlorhydria 2 (10.0) 0 (0.0)
 Thyroid function test abnormal 2 (10.0) 0 (0.0)
 Hypokalemia 2 (10.0) 1 (5.0)
 Hypesthesia 2 (10.0) 0 (0.0)
 Pyrexia 2 (10.0) 0 (0.0)
 Proteinuria 2 (10.0) 0 (0.0)
 γ-glutamyl transferase increased 1 (5.0) 1 (5.0)
 Diarrhea 1 (5.0) 1 (5.0)
 Autoimmune colitis 1 (5.0) 1 (5.0)
 Pneumonitis 1 (5.0) 1 (5.0)
  1. Listed are any grade TRAE found in ≥10% patients, and all grade 3–4 TRAEs